issuer: AGRANA Beteiligungs-AG F.-W.-Raiffeisen-Platz 1 A-1020 Wien phone: +43-1-21137-0 FAX: +43-1-21137-12926 mail: info.ab@agrana.com WWW: www.agrana.com ISIN: AT0000603709 indexes: WBI stockmarkets: Frankfurt, Berlin, Wien, Stuttgart language: English ...
http://resources.euroadhoc.com/documents/287/5/10186450/1/TKA_Q2_2018_Trading_Statement.pdf issuer: Telekom Austria AG Lassallestrasse 9 A-1020 Wien phone: 004350664 47500 FAX: mail: investor.relations@a1.group WWW: www.a1.group ISIN: AT0000720008 indexes: ATX, WBI stockmarkets: Wien language: English ...
issuer: Wolford Aktiengesellschaft Wolfordstrasse 1 A-6900 Bregenz phone: +43(0) 5574 690-1268 FAX: +43(0) 5574 690-1219 mail: investor@wolford.com WWW: http://company.wolford.com ISIN: AT0000834007 indexes: ATX GP stockmarkets: Wien, Frankfurt, New York language: English ...
Atrium European Real Estate Limited
issuer: Atrium European Real Estate Limited Seaton Place 11-15 UK-JE4 0QH St Helier Jersey / Channel Islands phone: +44 (0)20 7831 3113 FAX: mail: richard.sunderland@fticonsulting.com WWW: http://www.aere.com ISIN: JE00B3DCF752 indexes: stockmarkets: Wien, Luxembourg Stock Exchange language: English ...
issuer: FACC AG Fischerstraße 9 A-4910 Ried im Innkreis phone: +43/59/616-0 FAX: +43/59/616-81000 mail: office@facc.com WWW: www.facc.com ISIN: AT00000FACC2 indexes: stockmarkets: Wien language: English ...
Vienna (ots/PRNewswire) - People treated with Saxenda® (liraglutide 3 mg) for weight management lost an average of 8.1 kg after six months in a real-world clinical setting, in combination with diet and exercise. The data were presented this week at both the 25th European Congress on Obesity (ECO 2018) in Vienna, Austria and the 23rd Annual International Meeting of the ...
Hitachi Medical Systems Europe Holding AG
Vienna (ots/PRNewswire) - CDI, a potentially fatal disease,[2] is three times as deadly as MRSA[3],[4] and is estimated to cost the EU EUR3 billion per annum[5] New data presented today at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2017, demonstrate benefits of ...
Vienna (ots/PRNewswire) - CDI is one of the top ten hospital-acquired infections (HAIs) in European Hospitals[1] and is estimated to be three times as deadly as MRSA[2],[3] Data released at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2017 demonstrate the impact of CDI on the ...
Amsterdam and Vienna (ots/PRNewswire) - - iDose[4] proprietary reconstruction technique lowers operating costs by increasing tube life - iFlow intelligent workflow platform enables consistent image quality from operator-to-operator to reduce rescans Royal Philips (http://www.philips.com/) (NYSE: PHG; AEX: PHIA) ...
Amsterdam and Vienna (ots/PRNewswire) - Royal Philips (http://www.usa.philips.com/) (NYSE: PHG, AEX: PHIA), a global leader in health technology, today unveiled new advanced radiology solutions at the 2017 European Congress of Radiology (https://www.myesr.org/ecr-2017) (ECR), beginning March 1 at the Austria Center ...
Vienna (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Abstract: 69477 New data from the first health-related quality of life (HRQL) study related to post-meal or postprandial glucose (PPG) control, show that poor PPG control ...
United European Gastroenterology
Vienna (ots/PRNewswire) - It has been estimated that around one in 10 cases of bowel cancer can be linked to alcohol consumption[1] and the risk increases the more alcohol you drink[2]. One international group of researchers has estimated that the bowel cancer risk increases by 21% if you have two or three alcoholic drinks a day (1.5 to 6 units of alcohol) and by more than 50% if you have four or more drinks a day (6 ...
Takeda Pharmaceuticals Europe Ltd
Vienna (ots/PRNewswire) - FOR MEDICAL MEDIA Takeda Pharmaceuticals International GmbH ("Takeda") and Sunovion Pharmaceuticals Inc. ("Sunovion") today announced the results from three post-hoc analyses evaluating the efficacy and safety of Latuda(R) (lurasidone) in patients with schizophrenia at the 23rd European ...
Sunovion Pharmaceuticals Europe Ltd
Vienna (ots/PRNewswire) - Sunovion Pharmaceuticals Europe Ltd. will present 10 new research posters on LATUDA(R) (lurasidone), an atypical antipsychotic treatment for adults with schizophrenia, at the 23rd European Congress of Psychiatry (EPA). The meeting will be held 28-31 March 2015 in Vienna, Austria. "We are ...
Vienna, Austria (ots) - - MyStar Connect® software contributes to Sanofi's commitment in providing integrated diabetes care solutions, and supports healthcare professionals in clinical decision-making - - CE mark for MyStar Connect® - At the 50th annual meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria, Sanofi (EURONEXT: SAN and NYSE: SNY) announced today the upcoming launch of ...
Hilden, Germany And Vienna (ots/PRNewswire) - - Reliable diagnostic tools under development for mutations of calreticulin (CALR) are expected to benefit patients with blood disorders known as myeloproliferative neoplasms - QIAGEN acquired exclusive worldwide license for CALR biomarker from CeMM Vienna, whose ...
Vienna (ots/PRNewswire) - New integrated radiology solutions designed to deliver economic value, increase clinical performance Royal Philips will demonstrate advanced image quality, visualization and clinical decision support at the European Congress of Radiology [https://www.myesr.org/cms/website.php?id=/en/ecr_2014.htm ], March 6-10, in Vienna, Austria. Building on more than 20 years of digital imaging experience, the ...
Lugano, Switzerland & Vienna, Austria (ots) - New data presented at the 2012 meeting of the European Society of Medical Oncology (ESMO) in Vienna show antiemetic efficacy maintained across the chemotherapy cycles and a positive safety profile The oral formulation of palonosetron, the second generation 5-HT3 receptor ...
Vienna, Austria (ots/PRNewswire) - INTENDED FOR EUROPEAN MEDIA ONLY Results from a Phase I/II trial of the investigational compound lenvatinib (E7080), a multi-targeted, kinase inhibitor, in people with advanced hepatocellular cancer have been presented at the ESMO 2012 Congress (European Society for Medical ...